Skip to main content
. Author manuscript; available in PMC: 2014 Mar 13.
Published in final edited form as: Circulation. 2013 Feb 7;127(10):1116–1127. doi: 10.1161/CIRCULATIONAHA.112.000855

Figure 6.

Figure 6

SG-1002 does not provide protection in eNOS deficient mice. (A) Myocardial weights expressed as ratio of tibia length and (B) circulating BNP levels at 6 weeks of TAC in eNOS deficient (eNOS KO) sham, eNOS KO mice subjected to TAC (eNOS KO+TAC) and eNOS KO mice treated with SG-1002 (eNOS KO+TAC+SG-1002). (C) LVESD and (D) ejection fraction from 1 week to 6 weeks TAC. Results are expressed as mean ± SEM. **p<0.01 and ***p<0.001 vs. eNOS KO sham or Baseline.

HHS Vulnerability Disclosure